HPMA-Based Copolymers Carrying STAT3 Inhibitor Cucurbitacin-D as Stimulus-Sensitive Nanomedicines for Oncotherapy.
N-(2-hydroxypropyl) methacrylamide (HPMA)
cucurbitacin-D
immuno-oncotherapy
pH-controlled release
signal transducer and activator of transcription 3 (STAT3) inhibition
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
28 Jan 2021
28 Jan 2021
Historique:
received:
22
12
2020
revised:
22
01
2021
accepted:
23
01
2021
entrez:
2
2
2021
pubmed:
3
2
2021
medline:
3
2
2021
Statut:
epublish
Résumé
The study describes the synthesis, physicochemical properties, and biological evaluation of polymer therapeutics based on
Identifiants
pubmed: 33525658
pii: pharmaceutics13020179
doi: 10.3390/pharmaceutics13020179
pmc: PMC7911143
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Grantová Agentura České Republiky
ID : 17-08084S
Organisme : Ministerstvo Školství, Mládeže a Tělovýchovy
ID : LTAUSA18083
Références
Trends Biotechnol. 2009 Jan;27(1):11-7
pubmed: 19022512
Chem Rev. 2016 May 11;116(9):5338-431
pubmed: 27109701
Eur J Pharm Sci. 2010 Nov 20;41(3-4):473-82
pubmed: 20696244
J Control Release. 2012 Dec 28;164(3):346-54
pubmed: 22759979
Mol Pharm. 2018 Sep 4;15(9):3654-3663
pubmed: 29543465
Nat Rev Drug Discov. 2015 Aug;14(8):561-84
pubmed: 26228759
Pharmaceutics. 2019 Nov 05;11(11):
pubmed: 31694350
J Drug Target. 2004;12(8):477-89
pubmed: 15621674
Chem Mater. 2012 Mar 13;24(5):840-853
pubmed: 22707853
Cancer Lett. 2003 Jan 10;189(1):11-6
pubmed: 12445672
Acta Biomater. 2020 Apr 1;106:256-266
pubmed: 32058082
Biomaterials. 2020 Mar;235:119728
pubmed: 32044514
Angew Chem Int Ed Engl. 2009;48(11):1991-4
pubmed: 19191357
Oncogene. 2002 Oct 10;21(46):7001-10
pubmed: 12370822
JAKSTAT. 2013 Jan 1;2(1):e22882
pubmed: 24058788
J Control Release. 2000 Mar 1;65(1-2):271-84
pubmed: 10699287
Int J Pharm. 2008 Jan 22;347(1-2):118-27
pubmed: 17681440
Cancers (Basel). 2019 Mar 14;11(3):
pubmed: 30875788
Macromol Biosci. 2018 Jan;18(1):
pubmed: 28805040
Biomacromolecules. 2019 Apr 8;20(4):1798-1815
pubmed: 30785284
Biomacromolecules. 2018 Oct 8;19(10):4003-4013
pubmed: 30180562
Adv Drug Deliv Rev. 2011 Mar 18;63(3):136-51
pubmed: 20441782
Mol Cell Biochem. 2015 Nov;409(1-2):33-43
pubmed: 26169986
Eur J Pharm Biopharm. 2009 Mar;71(3):409-19
pubmed: 19070661
Sci Rep. 2016 Nov 08;6:36594
pubmed: 27824155
Physiol Res. 2016 Oct 20;65(Suppl 2):S233-S241
pubmed: 27762589
J Biol Chem. 2005 Sep 23;280(38):32979-88
pubmed: 16046414
Nat Rev Immunol. 2007 Jan;7(1):41-51
pubmed: 17186030
Cancer Res. 1986 Dec;46(12 Pt 1):6387-92
pubmed: 2946403
Target Oncol. 2016 Feb;11(1):101-6
pubmed: 26194363
J Cancer. 2018 Apr 19;9(10):1773-1781
pubmed: 29805703
Front Oncol. 2018 Aug 23;8:315
pubmed: 30191140
Biomacromolecules. 2012 Aug 13;13(8):2594-604
pubmed: 22793269
Nat Med. 2005 Dec;11(12):1314-21
pubmed: 16288283
J Control Release. 2020 May 10;321:718-733
pubmed: 32142741
Cancer. 2011 Jun 15;117(12):2735-46
pubmed: 21656752
Cancer Res. 2003 Mar 15;63(6):1270-9
pubmed: 12649187
Pharmacogn Rev. 2015 Jan-Jun;9(17):12-8
pubmed: 26009687
Molecules. 2018 Dec 18;23(12):
pubmed: 30567327
Cells. 2019 Dec 31;9(1):
pubmed: 31906106
Nat Rev Cancer. 2004 Feb;4(2):97-105
pubmed: 14964307
Nat Rev Clin Oncol. 2016 May;13(5):273-90
pubmed: 26977780
J Control Release. 2008 Apr 21;127(2):121-30
pubmed: 18304673
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Eur J Pharm Biopharm. 2015 Feb;90:90-6
pubmed: 25460144
Med Oncol. 2016 Apr;33(4):30
pubmed: 26913856
Mol Pharm. 2010 Aug 2;7(4):1015-26
pubmed: 20518512